Lobby organisation
Regeneron Pharmaceuticals Inc.
Company · Health & pharma · HQ: United States · Transparency Register entry
As of 7 November 2026, Regeneron Pharmaceuticals Inc. appears in 6 declared MEP meetings (6 different MEPs), most often with European People's Party.
In their own words
“Regeneron is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, Regeneron's unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments and product candidates in development, almost all of which were homegrown in Regeneron's laboratories.”
Read the rest of the statementShow less of the statement
“Regeneron's medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. More than 15,000 of our colleagues work across the globe, with offices in 12 countries and clinical trials underway in more than 100 countries. For more information see www.regeneron.com.”
Stated goals from the organisation's own Transparency Register filing.
Who they meet, and when
Which groups they meet
Share of this organisation's 6 declared meetings, by the meeting MEP's political group.
Meetings by year
Declared meetings per calendar year, 2026–2026. Bar length is relative to its busiest year (6 in 2026). All meetings were in one calendar year. Hatched: 2026 is a part-year - the record runs to 6 Nov 2026.
Group is each MEP's current political group, not necessarily the one they sat with at the time. Shares are rounded to whole percent.
The MEPs they meet most
The 6 most recent declared meetings
| Date | MEP | Subject |
|---|---|---|
| 30 Jun 2026 | Morten Løkkegaard | Biotech |
| 30 Jun 2026 | Carlo Ciccioli | Biotech Act |
| 18 Jun 2026 | Elena Nevado del Campo | Biotech Act |
| 16 Jun 2026 | Katri Kulmuni | Biotech I |
| 16 Jun 2026 | András Tivadar Kulja | Biotech Act |
| 21 Jan 2026 | Sirpa Pietikäinen | Skin diseases |
Meeting an MEP is a normal part of democratic life; the record is shown so anyone can see it.